Tag: Immuno oncology drug
Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors
Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety ... Read More
Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab
Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination ... Read More
APAC Biotech’s Immuno-oncology drug Apceden gets approved in India
The Indian FDA (CDSCO - Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market Apceden, a Dendritic cell-based autologous ... Read More